Tylenol maker’s stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a ‘major overreaction’

Kenvue, the Tylenol manufacturer, experienced a significant stock decline, wiping approximately 9% off its market capitalization, following a Wall Street Journal report suggesting Robert F. Kennedy Jr. would link Tylenol use during pregnancy to autism. Despite the initial market rout, Wall Street analysts from firms like BofA Securities and Canaccord Genuity are advising clients to 'buy the dip,' characterizing the sell-off as a 'major overreaction.' They cite minimal legal risk given a prior lawsuit dismissal, the lack of scientific evidence linking acetaminophen to autism, and official statements from HHS and medical bodies that refute such claims, indicating the fundamental business remains resilient.

Analysis

Kenvue Inc. (KVUE) experienced a significant stock depreciation, shedding approximately 9% of its market capitalization, catalyzed by a Wall Street Journal report suggesting a high-profile government official planned to link Tylenol use during pregnancy to autism. Despite the intraday slump nearing 15%, the market reaction is being framed as a 'major overreaction' by multiple Wall Street firms, including BofA Securities and Canaccord Genuity. This analyst consensus views the sell-off as a buying opportunity, citing the minimal legal risk underscored by the effective dismissal of a similar mass tort lawsuit in December 2023. The bullish case is further supported by the lack of scientific evidence for the claim, a position echoed by the FDA and the American College of Obstetricians and Gynecologists. With the Department of Health and Human Services (HHS) terming the report's claims as 'speculation,' the prevailing analytical view is that the fundamental business remains resilient and the primary risk is limited to headline-driven sentiment for a small consumer segment, not a material legal or financial threat.

Key Decisions for Investors

• Given the strong analyst consensus that the sell-off is an overreaction, investors could view the recent price decline as a tactical opportunity to initiate or add to positions in Kenvue, capitalizing on the dislocation between market sentiment and fundamental analysis.
• Monitor for any official communications from HHS or Robert F. Kennedy Jr.; a formal statement or campaign could extend volatility, whereas a lack of follow-through would likely validate the current 'buy the dip' thesis.
• Investors should assess the company's valuation against the backdrop of its legal risk profile, which analysts suggest is minimal due to the December 2023 court precedent, rather than pricing in a worst-case litigation scenario based on unsubstantiated claims.